Journal article
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Abstract
BACKGROUND: Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of raltegravir to the currently marketed twice daily formulation.
METHODS: In this randomised, double-blind, parallel-group, phase 3, non-inferiority study, we enrolled participants aged 18 years or older with HIV-1 RNA of 1000 or more copies per mL and no previous antiretroviral …
Authors
Cahn P; Kaplan R; Sax PE; Squires K; Molina J-M; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M
Journal
The Lancet HIV, Vol. 4, No. 11, pp. e486–e494
Publisher
Elsevier
Publication Date
11 2017
DOI
10.1016/s2352-3018(17)30128-5
ISSN
2352-3018